Valuation: Quest PharmaTech Inc.

Market Cap 33.83L 23.75L 21.21L 19.79L 17.98L 23Cr 34.16L 2.38Cr 92.92L 12Cr 89.19L 87.25L 38Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 43.68L 30.68L 27.39L 25.55L 23.21L 30Cr 44.11L 3.07Cr 1.2Cr 15Cr 1.15Cr 1.13Cr 49Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day-20.00%
1 week-20.00%
Current month-20.00%
3 months-20.00%
6 months-33.33%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
21/10/25 Other

Chief Executive Officer

10,00,000 0.5913%
21/10/25 Other

Chief Executive Officer

3,00,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
-20.00%-20.00%-42.86%-66.67% 23.72L
-3.19%-3.19%+44.60%+87.98% 7.47TCr
-15.86%-16.16%+2.68%+51.09% 5.87TCr
-2.39%+0.50%+3.41%+31.33% 4.84TCr
-6.64%-9.92%+287.84%+628.17% 4.31TCr
-0.77%-1.64%+27.83%+28.51% 4.25TCr
-4.26%-3.00%-0.77%+101.63% 4.14TCr
-2.13%+1.07%+7.51%+50.31% 3.13TCr
-2.92%-4.78%-13.23%-15.63% 2.39TCr
-1.84%-8.28%-38.45%+306.34% 2.22TCr
Average -5.98%-2.37%+27.86%+120.31% 3.86TCr
Weighted average by Cap. -5.05%-1.88%+42.12%+133.52%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.65L -11.29L -10.54L -10L -12Cr -18.19L -1.26Cr -49.48L -6.22Cr -47.49L -46.46L -20Cr 49.98L 35.1L 31.34L 29.24L 26.56L 34Cr 50.47L 3.51Cr 1.37Cr 17Cr 1.32Cr 1.29Cr 56Cr
Net Debt 8L 6L 5L 5L 4L 5.41Cr 8L 55.83L 21.84L 2.75Cr 20.96L 20.5L 8.84Cr 10L 7L 6L 6L 5L 6.7Cr 10L 69.23L 27.08L 3.41Cr 25.99L 25.42L 11Cr
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume